Library · Digestive & liver · Treatment of acromegaly and carcinoid syndrome
Octreotide (Sandostatin)
Sandostatin, SMS 201-995, Octreotide acetate
A synthetic somatostatin mimic that suppresses growth hormone and other endocrine secretions. Long a mainstay for acromegaly and neuroendocrine tumor symptoms like carcinoid syndrome, it is now paired with radionuclide therapy as standard care for some advanced NETs, and used first-line for acute esophageal variceal bleeding.
Research score 95/100. Reference only, not a dose.
- Hormone Regulation
- Gut Health
- Anti-inflammatory
- Appetite Suppression
- Blood Sugar Control
- Anti-cancer
- US status
- Prescription Only
- Approval
- FDA + EMA Approved
- Evidence
- FDA-approved Somatostatin analog. Standard of care for Acromegaly, Carcinoid syndrome, and VIPomas. Inhibits GH and various GI hormones.
- Research score
- 95 / 100
- Indication
- Multiple Approved Indications
- Origin
- Switzerland
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Binds somatostatin receptors, mainly SSTR2/5, lowering cAMP and calcium to suppress GH, IGF-1, and gut hormones, reduce splanchnic blood flow and motility, and slow tumor growth via cell-cycle arrest and reduced growth-factor signaling.
Safety file
Gallstones develop in a notable share of long-term users; GI upset is common; bradycardia and high blood sugar can occur.
- Injection site reactions
- Gallstones
- Diarrhea or constipation
- Blood sugar changes
- Nausea
- Abdominal pain